Mahesh Kb Parmar

Summary

Affiliation: National Institute for Medical Research
Country: UK

Publications

  1. pmc Take-home emergency naloxone to prevent heroin overdose deaths after prison release: rationale and practicalities for the N-ALIVE randomized trial
    John Strang
    King s College London, National Addiction Centre Institute of Psychiatry and the Maudsley, London, SE5 8AF, UK
    J Urban Health 90:983-96. 2013
  2. pmc Impact of lack-of-benefit stopping rules on treatment effect estimates of two-arm multi-stage (TAMS) trials with time to event outcome
    Babak Choodari-Oskooei
    London Hub for Trials Methodology Research, MRC Clinical Trials Unit, Aviation House, 125 Kingsway, WC2B 6NH, London
    Trials 14:23. 2013
  3. pmc Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial
    Matthew R Sydes
    MRC Clinical Trials Unit, London, UK
    Trials 13:168. 2012
  4. pmc Speeding up the evaluation of new agents in cancer
    Mahesh K B Parmar
    Clinical Trials Unit, London, UK
    J Natl Cancer Inst 100:1204-14. 2008
  5. pmc Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit
    Patrick Royston
    MRC Clinical Trials, London NW1 2DA UK
    Trials 12:81. 2011
  6. pmc How do multi-stage, multi-arm trials compare to the traditional two-arm parallel group design--a reanalysis of 4 trials
    F M S Barthel
    Department of Biostatistics, Institute of Psychiatry, King s College London, London, UK
    Trials 10:21. 2009
  7. pmc Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial
    Matthew R Sydes
    MRC Clinical Trials Unit, London, UK
    Trials 10:39. 2009

Collaborators

  • Michael A Bookman
  • Patrick Royston
  • Matthew R Sydes
  • Babak Choodari-Oskooei
  • John Strang
  • Nicholas D James
  • Noel W Clarke
  • David P Dearnaley
  • Karen Sanders
  • Malcolm D Mason
  • F M S Barthel
  • Jack Bowden
  • Sheila M Bird
  • Johann de Bono
  • John Dwyer
  • Gordana Jovic
  • Alastair W S Ritchie
  • John Anderson
  • George Thalmann
  • Charlene Green
  • Claire Amos
  • J Martin Russell
  • Friederike M S Barthel
  • Valerie Isham
  • Rachel C Morgan
  • P Royston

Detail Information

Publications7

  1. pmc Take-home emergency naloxone to prevent heroin overdose deaths after prison release: rationale and practicalities for the N-ALIVE randomized trial
    John Strang
    King s College London, National Addiction Centre Institute of Psychiatry and the Maudsley, London, SE5 8AF, UK
    J Urban Health 90:983-96. 2013
    ..Advocates call for implementation, while naysayers raise concerns. The issue does not need more public debate; it needs good science. ..
  2. pmc Impact of lack-of-benefit stopping rules on treatment effect estimates of two-arm multi-stage (TAMS) trials with time to event outcome
    Babak Choodari-Oskooei
    London Hub for Trials Methodology Research, MRC Clinical Trials Unit, Aviation House, 125 Kingsway, WC2B 6NH, London
    Trials 14:23. 2013
    ..In TAMS designs, the stopping rule applied at the interim stage(s) affects the sampling distribution of the treatment effect estimator, potentially inducing bias that needs addressing...
  3. pmc Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial
    Matthew R Sydes
    MRC Clinical Trials Unit, London, UK
    Trials 13:168. 2012
    ..We describe methodological and practical issues arising with (1) stopping recruitment to research arms following a pre-planned intermediate analysis and (2) adding a new research arm during the trial...
  4. pmc Speeding up the evaluation of new agents in cancer
    Mahesh K B Parmar
    Clinical Trials Unit, London, UK
    J Natl Cancer Inst 100:1204-14. 2008
    ..By using intermediate outcomes and testing a number of new agents (and combinations) simultaneously, the new design requires fewer patients. Three trials using this methodology are presented...
  5. pmc Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit
    Patrick Royston
    MRC Clinical Trials, London NW1 2DA UK
    Trials 12:81. 2011
    ..Such trials can terminate at any of the intermediate stages or the final stage...
  6. pmc How do multi-stage, multi-arm trials compare to the traditional two-arm parallel group design--a reanalysis of 4 trials
    F M S Barthel
    Department of Biostatistics, Institute of Psychiatry, King s College London, London, UK
    Trials 10:21. 2009
    ..To speed up the evaluation of new therapies, the multi-arm, multi-stage trial design was suggested previously by the authors...
  7. pmc Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial
    Matthew R Sydes
    MRC Clinical Trials Unit, London, UK
    Trials 10:39. 2009
    ..The MAMS design will potentially facilitate evaluation and testing of new therapies in this and other diseases...